Skip to main content

Day: October 31, 2025

DXS International plc ((AQSE: DXSP) – Final Results

DXS INTERNATIONAL PLC (AQSE: DXSP) ANNUAL RESULTS for the year ended 30 April 2025 The Board of DXS International plc (“the Company”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, is pleased to announce its audited Final Results for the year ended 30 April 2025. Financial highlights:Revenue increased by 5% to £3,469,917 (2024: £3,308,359). Core recurring revenue model remains resilient. Available cash at the period end was £428,957 plus unutilised debtor drawdowns of £245,043 (2024 £469,617). Loss for the year of £94,750 (2024: Loss of £4,738,686: a combination of increased amortisation of £1,020,916 and impairment of £4,378,114). The R&D tax credits were down – from £212,964 – 2024 to £80,398 -2025 – due to HMRC’s new restrictions for companies...

Continue reading

Facephi Reports Solid 1H25 Results, Expects Strong Acceleration in 2H25, and Provides 2025–2026 Financial Guidance

Facephi Reports Solid 1H25 Results, Expects Strong Acceleration in 2H25, and Provides 2025–2026 Financial GuidancePositive Free Cash Flow (+€0,01 mm) over the last 12 months in terms of constant currency (CC); representing an unprecedented milestone in the Company’s history. EBITDA near break-even, with a result of -€0,2 mm or +€0,1 mm in CC; showing a significant improvement compared to -€2,7 mm in H1 2024. Financial Projections 2025–2026: Revenue and EBITDA are expected to grow by +26% and +232% CAGR 2024–2026, respectively, with an estimated Free Cash Flow/EBITDA ratio of 39% for 2026.Alicante, October 30, 2025 – Facephi Biometría, SA (BME Growth: FACE; Euronext Growth Paris: ALPHI) (“Facephi” or the “Company”), a global leader in AI/ML-powered digital identity verification and anti-fraud protection solutions, today released...

Continue reading

Kalmar’s interim report January–September 2025: Improved profitability in the quarter

KALMAR CORPORATION, INTERIM REPORT JANUARY–SEPTEMBER 2025, 31 OCTOBER 2025 AT 9:00 AM (EET) Kalmar’s interim report January–September 2025: Improved profitability in the quarterRecord-high comparable operating profit margin of 13.8 percent, supported by Services and improved efficiency Global market uncertainty persisted, volatility in the tariff and trade policy landscape dampened decision-making Solid performance in Services with both increased orders received and profitability Equipment orders received declined from the comparison period by 20 percent, however, showing solid growth year-to-date Guidance for 2025 unchanged.July–September 2025 in brief:Orders received decreased by 10 percent and totalled EUR 375 (416) million Order book amounted to EUR 961 million (31 Dec 2024: EUR 955 million) Sales increased by 3 percent...

Continue reading

Tallinna Vesi’s third-quarter sales reached €18.2 million

The sales of AS Tallinna Vesi in the third quarter of 2025 were €18.2 million, increasing 10.8% compared to the same period last year. Revenue growth was most affected by a change in price due to the need for critical investments.  Aleksandr Timofejev, CEO of Tallinna Vesi, said that the third quarter was characterised by continued progress with planned investments and a commitment to the continuity of the vital service. “Summer is the busiest time of year for water and sewer pipeline construction projects, and our team made the most of it. Four important stormwater receiving systems have been completed or are nearing completion in various districts of Tallinn. This creates the conditions necessary for developing a stormwater network,” he said. Timofejev noted that creating modern stormwater solutions is essential for the functioning...

Continue reading

Good customer activity and strong credit quality led to solid results for the first nine months of 2025 Net profit of DKK 16.7 billion

Press releaseDanske BankBernstorffsgade 40DK-1577 København VTel. + 45 45 14 14 00 31 October 2025 Page 1 of 3Good customer activity and strong credit quality led to solid results for the first nine months of 2025 Net profit of DKK 16.7 billion Carsten Egeriis, Chief Executive Officer, comments on the financial results: “We delivered a solid financial result for the first nine months of 2025 following strong execution on strategic priorities according to our Forward ’28 strategy. Our financial performance was driven by resilient net interest income, continually strong net fee income, effective cost management and low impairments as a result of the strong credit quality of our loan portfolio. Increased customer activity, a growing corporate customer base and market share gains in the corporate segment drove growth in lending and...

Continue reading

New member of the Executive Management team of Realkredit Danmark A/S

Company announcement number 86/2025 – 31. October 2025 New member of the Executive Management team of Realkredit Danmark A/S Realkredit Danmark adds a new member to its Executive Management team. Thais Lærkholm will join the Executive Management team of Realkredit Danmark A/S with effect from 1 January 2026. Thais Lærkholm Jensen has been part of the Danske Bank Group since 2023, when he started as Head of Products at Realkredit Danmark. He has previously held senior management roles at Danmarks Nationalbank and The Boston Consulting Group. Following his appointment to the Executive Management team on 1 January 2026, Thais will continue as Head of Products, Business Development and Funding, and be responsible for strategy and business development. “Thais has played a significant role in creating value for Realkredit Danmark,...

Continue reading

Corbus Pharmaceuticals Announces Pricing of Public Offering

NORWOOD, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced the pricing of an underwritten public offering of 4,744,231 shares of its common stock at a public offering price of $13.00 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,025,000 shares of its common stock, at a public offering price of $12.9999 per pre-funded warrant, for a total public offering size of approximately $75 million, before deducting underwriting discounts and estimated offering expenses. The exercise price of the pre-funded warrants is $0.0001 per share. In addition, Corbus has granted the underwriters a 30-day option to purchase up to an additional 865,384 shares of its common stock on the...

Continue reading

Vistin Pharma ASA: Third quarter and YTD 2025 financial results

Vistin Pharma ASA: Third quarter and YTD 2025 financial results Oslo, Norway, 31st of October 2025 Vistin Pharma ASA (VISTN) today announces the financial results for the third quarter of 2025. Revenue in the third quarter ended at MNOK 109 compared to MNOK 106 in Q3 2024. The increase in revenue was driven by 10% higher sales volume. Revenue YTD 2025 ended at MNOK 342 compared to MNOK 316 YTD last year, an increase of 8% Third quarter EBITDA ended at MNOK 28 compared to MNOK 29 in Q3 2024. EBITDA of MNOK 28 positively affected by higher sales volume, offset by lower global metformin prices compared to same quarter last year. EBITDA for first three months of 2025 ended at MNOK 89 compared to MNOK 77 YTD 2024, an increase of 16%. The net profit ended at MNOK 18.5 (16.6) for the third quarter of 2025. All time high production volume in the...

Continue reading

Aalberts N.V.: Aalberts completes acquisition of Grand Venture Technology Limited

Utrecht, 31 October 2025 Aalberts completes acquisition of Grand Venture Technology Limited Aalberts announces successful completion of the acquisition of Grand Venture Technology Limited (GVT). With its head office in Singapore, GVT operates six facilities across Singapore, Malaysia and China, generating an annual revenue of SGD 160 million in 2024 and an adjusted EBITDA margin of 19% with approximately 1,800 employees. In July 2025, Aalberts announced that an agreement was reached for the proposed acquisition of GVT, a leading precision engineering solutions and service provider of components, mechatronics, assembly and testing mainly for semiconductor, analytical life sciences, medical, aerospace and industrial automation industries. With this transaction now completed, we are expanding into the strategically important Southeast Asian...

Continue reading

BW Energy: Update on Kudu appraisal well

BW Energy: Update on Kudu appraisal well  BW Energy provides an update on the Kharas-1 appraisal well, which has reached total depth and drilled multiple formations present across the Kudu license. The well was strategically designed to intersect several targets within a single borehole. While this approach did not allow for individual optimisation of each formation, it provided valuable geological data across the broader petroleum system. Preliminary results are encouraging. Several intervals show indications of hydrocarbon presence and reservoir potential, suggesting a working petroleum system at Kharas. Early analysis indicates that the K1 interval may contain hydrocarbons wetter than dry gas. A hydrocarbon migration front has been observed, and wireline operations are underway to assess reservoir quality, fluid type, and pressure characteristics. A...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.